Standard Engineering Technology Ltd

Q2 FY25 Earnings Call Analysis

Industrial Manufacturing

Full Stock Analysis
fundraise: No informationcapex: Yesrevenue: Category 2margin: Category 3orderbook: Yes
💰

fundraise

Any current/future new fundraising through debt or equity?

- There is no explicit mention of any current or future fundraising through debt or equity in the call. - The company highlights strong cash and cash equivalents of INR209 crores, providing significant financial flexibility. - They emphasize disciplined management of working capital (173 days) and focus on strategic capital allocation. - Management discusses planned capex of INR40-50 crores for existing facility upgrades and INR150-180 crores for a new greenfield project but does not specify funding sources. - No plans for raising funds via equity or debt were indicated; the company relies on existing financial strength and internal accruals for expansions. - They remain open to M&A if opportunities arise but provided no indication of requiring external funding for such activities.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- Standard Glass Lining Technology Limited is investing INR40-50 crores over the next 1 to 1.5 years to mechanize and automate existing manufacturing facilities, including adding robots and upgrading processes. - A new greenfield project is underway with planned capital expenditure of INR150-180 crores for a heavy engineering facility featuring 100 mm fabrication thickness and 110-ton crane capacity, expected to be completed in 15-18 months. - The company is expanding capacity for shell and tube glass lining heat exchangers to produce up to 300 units monthly starting January 2026, to drive growth. - Additional investments are planned to increase manufacturing capacity threefold, including automation, polishing, welding improvements, and new facility modifications. - No major capex planned for the U.S. subsidiary in South Carolina; it will act mainly as a stock and service point initially. - Future M&A opportunities will be considered if the right targets emerge.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- The company expects steady year-on-year revenue growth of 20% to 25% over the next several years. - Driven by increasing enquiries, especially from Pharma CDMO clients, with no expected slowdown. - Expansion in product lines, capacities, and automation efforts will support growth. - New facility and capacity enhancements aim to nearly double revenue potential, targeting INR2,000 crores top line with current and new facilities combined. - Export revenues expected to rise from current 13%-15% to 30%-40% in 5-6 years, enhancing overall growth and profitability. - Shell and tube glass lining heat exchanger production capacity increasing to 300 units per month by early 2026, key growth driver. - Continued strategic focus on high-margin product segments and international market penetration supports sustained volume growth.
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Management expects steady year-on-year growth of 20% to 25% in revenue, driven by increased orders from Pharma CDMO and specialty chemicals sectors. - EBITDA margin expansion was aided by better pricing, cost optimizations, and increased exports; export EBITDA contribution is around 25%. - Export revenue is targeted to increase from 13%-15% currently to 30%-40% over the next 5-6 years, supporting margin improvement. - Capacity expansions including automation and a new greenfield facility expected to triple manufacturing capacity are underway, enabling revenue potential of INR2,000 crores and beyond. - Full-fledged sales of shell and tube glass lining heat exchangers starting June 2026 expected to drive growth and margins. - Working capital days targeted to be reduced to 150 days to improve cash flows. - Overall, management remains confident of maintaining 20%-25% revenue growth with sustainable EBITDA margins and enhanced profitability in coming years.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- The company does not follow an order book disclosure philosophy and hence does not officially disclose the order book. - For the current year, they mention being almost full in terms of order capacity ("this year, we are completely almost full"). - Order inflow from international markets is reported as very good this year. - The company is experiencing increased enquiries and orders, especially from pharma and specialty chemicals sectors. - They are planning significant capacity expansions to meet growing demand, including new facilities and automation. - Shell and tube heat exchanger product line is expected to be a key growth driver starting full-fledged sales from June 2026.